Boehringer Ingelheim and its partner Eli Lilly report that the FDA has approved their once-daily type II diabetes pill linagliptin (Tradjenta).

Tradjenta will be used to improve blood glucose control in adults with type II diabetes, in tandem with diet and exercise. Data from eight clinical studies involving about 3,800 patients with type 2 diabetes and Tradjenta has been studied as a stand-alone therapy and in combination with other type 2 diabetes therapies including metformin, glimepiride and pioglitazone.

The most common side effects seen in studies were upper respiratory infection, stuffy or runny nose, sore throat, muscle pain and headache.